What is a clinical trial?
Although there are many definitions of clinical trials, they are generally considered to be biomedical or health-related research studies in human beings that follow a pre-defined protocol. ClinicalTrials.gov includes both interventional and observational types of studies. Interventional studies are those in which the research subjects are assigned by the investigator to a treatment or other intervention, and their outcomes are measured. Observational studies are those in which individuals are observed and their outcomes are measured by the investigators.
What is informed consent?
Informed consent is the process of learning the key facts about a clinical trial before deciding whether or not to participate. It is also a continuing process throughout the study to provide information for participants. To help someone decide whether or not to participate, the doctors and nurses involved in the trial explain the details of the study. If the participant’s native language is not English, translation assistance can be provided. Then the research team provides an informed consent document that includes details about the study, such as its purpose, duration, required procedures, and key contacts. Risks and potential benefits are explained in the informed consent document. The participant then decides whether or not to sign the document. Informed consent is not a contract, and the participant may withdraw from the trial at any time.
What are side effects and adverse reactions?
Side effects are any undesired actions or effects of the experimental drug or treatment. Negative or adverse effects may include headache, nausea, hair loss, skin irritation, or other physical problems. Experimental treatments must be evaluated for both immediate and long-term side effects.
How is the safety of the participant protected?
The ethical and legal codes that govern medical practice also apply to clinical trials. In addition, most clinical research is federally regulated with built in safeguards to protect the participants. The trial follows a carefully controlled protocol, a study plan which details what researchers will do in the study. As a clinical trial progresses, researchers report the results of the trial at scientific meetings, to medical journals, and to various government agencies. Individual participants’ names will remain secret and will not be mentioned in these reports (See Confidentiality Regarding Trial Participants).
What should people consider before participating in a trial?
People should know as much as possible about the clinical trial and feel comfortable asking the members of the health care team questions about it, the care expected while in a trial, and the cost of the trial. The following questions might be helpful for the participant to discuss with the health care team. Some of the answers to these questions are found in the informed consent document.
- What is the purpose of the study?
- Who is going to be in the study?
- Why do researchers believe the experimental treatment being tested may be effective? Has it been tested before?
- What kinds of tests and experimental treatments are involved?
- How do the possible risks, side effects, and benefits in the study compare with my current treatment?
- How might this trial affect my daily life?
- How long will the trial last?
- Will hospitalization be required?
- Who will pay for the experimental treatment?
- Will I be reimbursed for other expenses?
- What type of long-term follow up care is part of this study?
- How will I know that the experimental treatment is working? Will results of the trials be provided to me?
- Who will be in charge of my care?
What kind of preparation should a potential participant make for the meeting with the research coordinator or doctor?
- Plan ahead and write down possible questions to ask.
- Ask a friend or relative to come along for support and to hear the responses to the questions.
- Bring a tape recorder to record the discussion to replay later.
Every clinical trial in the U.S. must be approved and monitored by an Institutional Review Board (IRB) to make sure the risks are as low as possible and are worth any potential benefits. An IRB is an independent committee of physicians, statisticians, community advocates, and others that ensures that a clinical trial is ethical and the rights of study participants are protected. All institutions that conduct or support biomedical research involving people must, by federal regulation, have an IRB that initially approves and periodically reviews the research.
Does a participant continue to work with a primary health care provider while in a trial?
Yes. Most clinical trials provide short-term treatments related to a designated illness or condition, but do not provide extended or complete primary health care. In addition, by having the health care provider work with the research team, the participant can ensure that other medications or treatments will not conflict with the protocol.
Can a participant leave a clinical trial after it has begun?
Yes. A participant can leave a clinical trial, at any time. When withdrawing from the trial, the participant should let the research team know about it, and the reasons for leaving the study.
Where do the ideas for trials come from?
Ideas for clinical trials usually come from researchers. After researchers test new therapies or procedures in the laboratory and in animal studies, the experimental treatments with the most promising laboratory results are moved into clinical trials. During a trial, more and more information is gained about an experimental treatment, its risks and how well it may or may not work.
Who sponsors clinical trials?
Clinical trials are sponsored or funded by a variety of organizations or individuals such as physicians, medical institutions, foundations, voluntary groups, and pharmaceutical companies, in addition to federal agencies such as the National Institutes of Health (NIH), the Department of Defense (DOD), and the Department of Veteran’s Affairs (VA). Trials can take place in a variety of locations, such as hospitals, universities, doctors’ offices, or community clinics.
What is a protocol?
A protocol is a study plan on which all clinical trials are based. The plan is carefully designed to safeguard the health of the participants as well as answer specific research questions. A protocol describes what types of people may participate in the trial; the schedule of tests, procedures, medications, and dosages; and the length of the study. While in a clinical trial, participants following a protocol are seen regularly by the research staff to monitor their health and to determine the safety and effectiveness of their treatment.
What is a placebo?
A placebo is an inactive pill, liquid, or powder that has no treatment value. In clinical trials, experimental treatments are often compared with placebos to assess the experimental treatment’s effectiveness. In some studies, the participants in the control group will receive a placebo instead of an active drug or experimental treatment.
What is a control or control group?
A control is the standard by which experimental observations are evaluated. In many clinical trials, one group of patients will be given an experimental drug or treatment, while the control group is given either a standard treatment for the illness or a placebo.
What are the different types of clinical trials?
Treatment trials test experimental treatments, new combinations of drugs, or new approaches to surgery or radiation therapy.
Prevention trials look for better ways to prevent disease in people who have never had the disease or to prevent a disease from returning. These approaches may include medicines, vaccines, vitamins, minerals, or lifestyle changes.
Diagnostic trials are conducted to find better tests or procedures for diagnosing a particular disease or condition.
Screening trials test the best way to detect certain diseases or health conditions.
Quality of Life trials (or Supportive Care trials) explore ways to improve comfort and the quality of life for individuals with a chronic illness.
What are the phases of clinical trials?
Clinical trials are conducted in phases. The trials at each phase have a different purpose and help scientists answer different questions:
In Phase I trials, researchers test an experimental drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase II trials, the experimental study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase III trials, the experimental study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the experimental drug or treatment to be used safely.
In Phase IV trials, post marketing studies delineate additional information including the drug’s risks, benefits, and optimal use.
What is “expanded access”?
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Most human use of investigational new drugs takes place in controlled clinical trials conducted to assess the safety and efficacy of new drugs. Data from these trials are used to determine whether a drug is safe and effective, and serve as the basis for the drug marketing application. Sometimes, patients do not qualify for these controlled trials because of other health problems, age, or other factors, or are otherwise unable to enroll in such trials (e.g., a patient may not live sufficiently close to a clinical trial site).
For patients who cannot participate in a clinical trial of an investigational drug, but have a serious disease or condition that may benefit from treatment with the drug,FDA regulations enable manufacturers of such drugs to provide those patients access to the drug under certain situations, known as “expanded access.” For example, the drug cannot expose patients to unreasonable risks given the severity of the disease to be treated and the patient does not have any other satisfactory therapeutic options (e.g., an approved drug that could be used to treat the patient’s disease or condition). The manufacturer must be willing to make the drug available for expanded access use. The primary intent of expanded access is to provide treatment for a patient’s disease or condition, rather than to collect data about the study drug.
Some investigational drugs are available for treatment use from pharmaceutical manufacturers through expanded access programs listed in ClinicalTrials.gov. If you or a loved one is interested in treatment with an investigational drug under an expanded access protocol listed in ClinicalTrials.gov, review the protocol eligibility criteria and inquire at the Contact Information number. If there is not an expanded access protocol listed in ClinicalTrials.gov, you or your health care provider may contact a manufacturer of an investigational drug directly to ask about expanded access programs.
1.Describe the phases of clinical trials?
Ans:- These are the following four phases of the clinical trials:
Phase 1: Test a new drug or treatment to a small group of people (20-80) to evaluate its safety.
Phase 2: The experimental drug or treatment is given to a large group of people (100-300) to see that the drug is effective or not for that treatment.
Phase 3: The experimental drug or treatment is given to a large group of people (1000-3000) to see its effectiveness, monitor side effects and compare it to commonly used treatments.
Phase 4: The 4 phase study includes the post marketing studies including the drug’s risk, benefits etc.
2. Describe the validation procedure? How would you perform the validation for TLG as well as analysis data set?
Ans:- Validation procedure is used to check the output of the SAS program generated by the source programmer. In this process validator write the program and generate the output. If this output is same as the output generated by the SAS programmer’s output then the program is considered to be valid. We can perform this validation for TLG by checking the output manually and for analysis data set it can be done using PROC COMPARE.
3. How would you perform the validation for the listing, which has 400 pages?
Ans:- It is not possible to perform the validation for the listing having 400 pages manually. To do this, we convert the listing in data sets by using PROC RTF and then after that we can compare it by using PROC COMPARE.
4. Can you use PROC COMPARE to validate listings? Why?
Ans:- Yes, we can use PROC COMPARE to validate the listing because if there are many entries (pages) in the listings then it is not possible to check them manually. So in this condition we use PROC COMPARE to validate the listings.
5. How would you generate tables, listings and graphs?
Ans:- We can generate the listings by using the PROC REPORT. Similarly we can create the tables by using PROC FREQ, PROC MEANS, and PROC TRANSPOSE and PROC REPORT. We would generate graph, using proc Gplot etc.
6. How many tables can you create in a day?
Ans:- Actually it depends on the complexity of the tables if there are same type of tables then, we can create 1-2-3 tables in a day.
7. What are all the PROCS have you used in your experience?
Ans:- I have used many procedures like proc report, proc sort, proc format etc. I have used proc report to generate the list report, in this procedure I have used subjid as order variable and trt_grp, sbd, dbd as display variables.
8. Describe the data sets you have come across in your life?
Ans:- I have worked with demographic, adverse event , laboratory, analysis and other data sets.
9. How would you submit the docs to FDA? Who will submit the docs?
Ans:- We can submit the docs to FDA by e-submission. Docs can be submitted to FDA using
Define.pdf or define.Xml formats. In this doc we have the documentation about macros and program and E-records also. Statistician or project manager will submit this doc to FDA.
10. What are the docs do you submit to FDA?
Ans:- We submit ISS and ISE documents to FDA.
11. Can u share your CDISC experience? What version of CDISC SDTM have you used?
Ans: I have used version 3.1.1 of the CDISC SDTM.
12. Tell me the importance of the SAP?
Ans:- This document contains detailed information regarding study objectives and statistical methods to aid in the production of the Clinical Study Report (CSR) including summary tables, figures, and subject data listings for Protocol. This document also contains documentation of the program variables and algorithms that will be used to generate summary statistics and statistical analysis.
13. Tell me about your project group? To whom you would report/contact?
My project group consisting of six members, a project manager, two statisticians, lead programmer and two programmers.
I usually report to the lead programmer. If I have any problem regarding the programming I would contact the lead programmer.
If I have any doubt in values of variables in raw dataset I would contact the statistician. For example the dataset related to the menopause symptoms in women, if the variable sex having the values like F, M. I would consider it as wrong; in that type of situations I would contact the statistician.
14. Explain SAS documentation.
SAS documentation includes programmer header, comments, titles, footnotes etc. Whatever we type in the program for making the program easily readable, easily understandable are in called as SAS documentation.
15. How would you know whether the program has been modified or not?
I would know the program has been modified or not by seeing the modification history in the program header.
16. Project status meeting?
It is a planetary meeting of all the project managers to discuss about the present Status of the project in hand and discuss new ideas and options in improving the Way it is presently being performed.
17. Describe clin-trial data base and oracle clinical
Clintrial, the market’s leading Clinical Data Management System (CDMS).Oracle Clinical or OC is a database management system designed by Oracle to provide data management, data entry and data validation functionalities to Clinical Trials process.18. Tell me about MEDRA and what version of MEDRA did you use in your project?Medical dictionary of regulatory activities. Version 10
19. Describe SDTM?
CDISC’s Study Data Tabulation Model (SDTM) has been developed to standardize what is submitted to the FDA.
20. What is CRT?
Case Report Tabulation, Whenever a pharmaceutical company is submitting an NDA, conpany has to send the CRT’s to the FDA.
21. What is annotated CRF?
Annotated CRF is a CRF(Case report form) in which variable names are written next the spaces provided to the investigator. Annotated CRF serves as a link between the raw data and the questions on the CRF. It is a valuable toll for the programmers and statisticians.
22. What do you know about 21CRF PART 11?
Title 21 CFR Part 11 of the Code of Federal Regulations deals with the FDA guidelines on electronic records and electronic signatures in the United States. Part 11, as it is commonly called, defines the criteria under which electronic records and electronic signatures are considered to be trustworthy, reliable and equivalent to paper records.
23 What are the contents of AE dataset? What is its purpose?
What are the variables in adverse event datasets?The adverse event data set contains the SUBJID, body system of the event, the preferred term for the event, event severity. The purpose of the AE dataset is to give a summary of the adverse event for all the patients in the treatment arms to aid in the inferential safety analysis of the drug.
24 What are the contents of lab data? What is the purpose of data set?
The lab data set contains the SUBJID, week number, and category of lab test, standard units, low normal and high range of the values. The purpose of the lab data set is to obtain the difference in the values of key variables after the administration of drug.
25.How did you do data cleaning? How do you change the values in the data on your own?
I used proc freq and proc univariate to find the discrepancies in the data, which I reported to my manager.
26.Have you created CRT’s, if you have, tell me what have you done in that?
Yes I have created patient profile tabulations as the request of my manager and and the statistician. I have used PROC CONTENTS and PROC SQL to create simple patient listing which had all information of a particular patient including age, sex, race etc.
27. Have you created transport files?
Yes, I have created SAS Xport transport files using Proc Copy and data step for the FDA submissions. These are version 5 files. we use the libname engine and the Proc Copy procedure, One dataset in each xport transport format file. For version 5: labels no longer than 40 bytes, variable names 8 bytes, character variables width to 200 bytes. If we violate these constraints your copy procedure may terminate with constraints, because SAS xport format is in compliance with SAS 5 datasets.
Libname sdtm “c:\sdtm_data”;Libname dm xport “c:\dm.xpt”;
In = sdtm;
Out = dm;
28. How did you do data cleaning? How do you change the values in the data on your own?
I used proc freq and proc univariate to find the discrepancies in the data, which I reported to my manager.
CDISC- Clinical data interchange standards consortium.They have different data models, which define clinical data standards for pharmaceutical industry.
SDTM – It defines the data tabulation datasets that are to be sent to the FDA for regulatory submissions.
ADaM – (Analysis data Model)Defines data set definition guidance for creating analysis data sets.
ODM – XML – based data model for allows transfer of XML based data .
Define.xml – for data definition file (define.pdf) which is machine readable.
ICH E3: Guideline, Structure and Content of Clinical Study Reports
ICH E6: Guideline, Good Clinical Practice
ICH E9: Guideline, Statistical Principles for Clinical Trials
Title 21 Part 312.32: Investigational New Drug Application
30. Have you ever done any Edit check programs in your project, if you have, tell me what do you know about edit check programs?
Yes I have done edit check programs .Edit check programs – Data validation.
1.Data Validation – proc means, proc univariate, proc freq.Data Cleaning – finding errors.
2.Checking for invalid character values.Proc freq data = patients;Tables gender dx ae / nocum nopercent;Run;Which gives frequency counts of unique character values.
3. Proc print with where statement to list invalid data values.[systolic blood pressure – 80 to 100][diastolic blood pressure – 60 to 120]
4. Proc means, univariate and tabulate to look for outliers.Proc means – min, max, n and mean.Proc univariate – five highest and lowest values[ stem leaf plots and box plots]
5. PROC FORMAT – range checking
6. Data Analysis – set, merge, update, keep, drop in data step.
7. Create datasets – PROC IMPORT and data step from flat files.
8. Extract data – LIBNAME.9. SAS/STAT – PROC ANOVA, PROC REG.
10. Duplicate Data – PROC SORT Nodupkey or NoduplicateNodupkey – only checks for duplicates in BYNoduplicate – checks entire observation (matches all variables)For getting duplicate observations first sort BY nodupkey and merge it back to the original dataset and keep only records in original and sorted.
11.For creating analysis datasets from the raw data sets I used the PROC FORMAT, and rename and length statements to make changes and finally make a analysis data set.
31. What is Verification?
The purpose of the verification is to ensure the accuracy of the final tables and the quality of SAS programs that generated the final tables. According to the instructions SOP and the SAP I selected the subset of the final summary tables for verification.
E.g Adverse event table, baseline and demographic characteristics table.The verification results were verified against with the original final tables and all discrepancies if existed were documented.
32. What is Program Validation?
Its same as macro validation except here we have to validate the programs i.e according to the SOP I had to first determine what the program is supposed to do, see if they work as they are supposed to work and create a validation document mentioning if the program works properly and set the status as pass or fail.Pass the input parameters to the program and check the log for errors.
33. What do you lknow about ISS and ISE, have you ever produced these reports?
ISS (Integrated summary of safety):Integrates safety information from all sources (animal, clinical pharmacology, controlled and uncontrolled studies, epidemiologic data). “ISS is, in part, simply a summation of data from individual studies and, in part, a new analysis that goes beyond what can be done with individual studies.”ISE (Integrated Summary of efficacy)ISS & ISE are critical components of the safety and effectiveness submission and expected to be submitted in the application in accordance with regulation. FDA’s guidance Format and Content of Clinical and Statistical Sections of Application gives advice on how to construct these summaries. Note that, despite the name, these are integrated analyses of all relevant data, not summaries.
34. Explain the process and how to do Data Validation?
I have done data validation and data cleaning to check if the data values are correct or if they conform to the standard set of rules.A very simple approach to identifying invalid character values in this file is to use PROC FREQ to list all the unique values of these variables. This gives us the total number of invalid observations. After identifying the invalid data …we have to locate the observation so that we can report to the manager the particular patient number.Invalid data can be located using the data _null_ programming.
Following is e.g
INFILE “C:PATIENTS,TXT” PAD;FILE PRINT; ***SEND OUTPUT TO THE OUTPUT WINDOW;
TITLE “LISTING OF INVALID DATA”;
***NOTE: WE WILL ONLY INPUT THOSEVARIABLES OF INTEREST;INPUT @1 PATNO $3.@4 GENDER $1.@24 DX $3.@27 AE $1.;
***CHECK GENDER;IF GENDER NOT IN (‘F’,’M’,’ ‘) THEN PUT PATNO= GENDER=;
IF VERIFY(DX,’ 0123456789′) NE 0
THEN PUT PATNO= DX=;
IF AE NOT IN (‘0′,’1′,’ ‘) THEN PUT PATNO= AE=;
For data validation of numeric values like out of range or missing values I used proc print with a where statement.
PROC PRINT DATA=CLEAN.PATIENTS;
WHERE HR NOT BETWEEN 40 AND 100 AND
HR IS NOT MISSING OR
SBP NOT BETWEEN 80 AND 200 AND
SBP IS NOT MISSING OR
DBP NOT BETWEEN 60 AND 120 AND
DBP IS NOT MISSING;TITLE “OUT-OF-RANGE VALUES FOR NUMERICVARIABLES”;
VAR HR SBP DBP;
If we have a range of numeric values ‘001’ – ‘999’ then we can first use user defined format and then use proc freq to determine the invalid values.
VALUE $GENDER ‘F’,’M’ = ‘VALID” ‘ = ‘MISSING’OTHER = ‘MISCODED’;
VALUE $DX ‘001’ – ‘999’= ‘VALID” ‘ = ‘MISSING’OTHER = ‘MISCODED’;
VALUE $AE ‘0’,’1′ = ‘VALID” ‘ = ‘MISSING’OTHER = ‘MISCODED’;
One of the simplest ways to check for invalid numeric values is to run either PROC MEANS or PROC UNIVARIATE.We can use the N and NMISS options in the Proc Means to check for missing and invalid data. Default (n nmiss mean min max stddev).The main advantage of using PROC UNIVARIATE (default n mean std skewness kurtosis) is that we get the extreme values i.e lowest and highest 5 values which we can see for data errors. If u want to see the patid for these particular observations …..state and ID patno statement in the univariate procedure.
35. Roles and responsibilities?
Develop programming for report formats (ISS & ISE shell) required by the regulatory authorities.Update ISS/ISE shell, when required.
Clinical Study Team:
Provide information on safety and efficacy findings, when required.Provide updates on safety and efficacy findings for periodic reporting.
Draft ISS and ISE shell.Update shell, when appropriate.Analyze and report data in approved format, to meet periodic reporting requirements.
36. Explain Types of Clinical trials study you come across?
Single Blind Study
When the patients are not aware of which treatment they receive.
Double Blind Study
When the patients and the investigator are unaware of the treatment group assigned.
Triple Blind Study
Triple blind study is when patients, investigator, and the project team are unaware of the treatments administered.
37. What are the domains/datasets you have used in your studies?
38. Can you list the variables in all the domains?
Demog: Usubjid, Patient Id, Age, Sex, Race, Screening Weight, Screening Height, BMI etc
Adverse Events: Protocol no, Investigator no, Patient Id, Preferred Term, Investigator Term, (Abdominal dis, Freq urination, headache, dizziness, hand-food syndrome, rash, Leukopenia, Neutropenia) Severity, Seriousness (y/n), Seriousness Type (death, life threatening, permanently disabling), Visit number, Start time, Stop time, Related to study drug?
Vitals: Subject number, Study date, Procedure time, Sitting blood pressure, Sitting Cardiac Rate, Visit number, Change from baseline, Dose of treatment at time of vital sign, Abnormal (yes/no), BMI, Systolic blood pressure, Diastolic blood pressure.
ECG: Subject no, Study Date, Study Time, Visit no, PR interval (msec), QRS duration (msec), QT interval (msec), QTc interval (msec), Ventricular Rate (bpm), Change from baseline, Abnormal.
Labs: Subject no, Study day, Lab parameter (Lparm), lab units, ULN (upper limit of normal), LLN (lower limit of normal), visit number, change from baseline, Greater than ULN (yes/no), lab related serious adverse event (yes/no).Medical History: Medical Condition, Date of Diagnosis (yes/no), Years of onset or occurrence, Past condition (yes/no), Current condition (yes/no).
PhysicalExam: Subject no, Exam date, Exam time, Visit number, Reason for exam, Body system, Abnormal (yes/no), Findings, Change from baseline (improvement, worsening, no change), Comments
39. Give me the example of edit ckecks you made in your programs?Examples of Edit Checks
Demog:Weight is outside expected rangeBody mass index is below expected
( check weight and height)
Age is not within expected range.
DOB is greater than the Visit date or not..
Gender value is a valid one or invalid. etc
Stop is before the start or visit Start is before birthdate Study medicine discontinued due to adverse event but completion indicated (COMPLETE =1)
Result is within the normal range but abnormal is not blank or ‘N’Result is outside the normal range but abnormal is blank
Diastolic BP > Systolic BP
Visit date prior to Screen datePhysicalPhysical exam is normal but comment included
40. What are the advantages of using SAS in clinical data management? Why should not we use other software products in managing clinical data?
ADVANTAGES OF USING A SAS®-BASED SYSTEM
Less hardware is required.
A Typical SAS®-based system can utilize a standard file server to store its databases and does not require one or more dedicated servers to handle the application load. PC SAS® can easily be used to handle processing, while data access is left to the file server. Additionally, as presented later in this paper, it is possible to use the SAS® product SAS®/Share to provide a dedicated server to handle data transactions.
Fewer personnel are required.
Systems that use complicated database software often require the hiring of one ore more DBA’s (Database Administrators) who make sure the database software is running, make changes to the structure of the database, etc. These individuals often require special training or background experience in the particular database application being used, typically Oracle. Additionally, consultants are often required to set up the system and/or studies since dedicated servers and specific expertise requirements often complicate the process.Users with even casual SAS® experience can set up studies. Novice programmers can build the structure of the database and design screens. Organizations that are involved in data management almost always have at least one SAS® programmer already on staff. SAS® programmers will have an understanding of how the system actually works which would allow them to extend the functionality of the system by directly accessing SAS® data from outside of the system.Speed of setup is dramatically reduced. By keeping studies on a local file server and making the database and screen design processes extremely simple and intuitive, setup time is reduced from weeks to days.All phases of the data management process become homogeneous. From entry to analysis, data reside in SAS® data sets, often the end goal of every data management group. Additionally, SAS® users are involved in each step, instead of having specialists from different areas hand off pieces of studies during the project life cycle.No data conversion is required. Since the data reside in SAS® data sets natively, no conversion programs need to be written.Data review can happen during the data entry process, on the master database. As long as records are marked as being double-keyed, data review personnel can run edit check programs and build queries on some patients while others are still being entered.Tables and listings can be generated on live data. This helps speed up the development of table and listing programs and allows programmers to avoid having to make continual copies or extracts of the data during testing.43. Have you ever had to follow SOPs or programming guidelines?SOP describes the process to assure that standard coding activities, which produce tables, listings and graphs, functions and/or edit checks, are conducted in accordance with industry standards are appropriately documented.It is normally used whenever new programs are required or existing programs required some modification during the set-up, conduct, and/or reporting clinical trial data.44. Describe the types of SAS programming tasks that you performed: Tables? Listings? Graphics? Ad hoc reports? Other?Prepared programs required for the ISS and ISE analysis reports. Developed and validated programs for preparing ad-hoc statistical reports for the preparation of clinical study report. Wrote analysis programs in line with the specifications defined by the study statistician. Base SAS (MEANS, FREQ, SUMMARY, TABULATE, REPORT etc) and SAS/STAT procedures (REG, GLM, ANOVA, and UNIVARIATE etc.) were used for summarization, Cross-Tabulations and statistical analysis purposes. Created Statistical reports using Proc Report, Data _null_ and SAS Macro. Created, derived and merged and pooled datasets,listings and summary tables for Phase-I and Phase-II of clinical trials.45. Have you been involved in editing the data or writing data queries?If your interviewer asks this question, the u should ask him what he means by editing the data… and data queries…
41. Are you involved in writing the inferential analysis plan? Table’s specifications?
42. What do you feel about hardcoding?
Programmers sometime hardcode when they need to produce report in urgent. But it is always better to avoid hardcoding, as it overrides the database controls in clinical data management. Data often change in a trial over time, and the hardcode that is written today may not be valid in the future.Unfortunately, a hardcode may be forgotten and left in the SAS program, and that can lead to an incorrect database change.
43. How do you write a test plan?
Before writing “Test plan” you have to look into on “Functional specifications”. Functional specifications itself depends on “Requirements”, so one should have clear understanding of requirements and functional specifications to write a test plan.
44. What is the difference between verification and validation?
Although the verification and validation are close in meaning, “verification” has more of a sense of testing the truth or accuracy of a statement by examining evidence or conducting experiments, while “validate” has more of a sense of declaring a statement to be true and marking it with an indication of official sanction.
45.What other SAS features do you use for error trapping and data validation?
Conditional statements, if then else.
46. What is PROC CDISC?
It is new SAS procedure that is available as a hotfix for SAS 8.2 version and comes as a part withSAS 9.1.3 version.
PROC CDISC is a procedure that allows us to import (and export XML files that are compliant with the CDISC ODM version 1.2 schema.
For more details refer SAS programming in the Pharmaceutical Industry text book.
47) What is LOCF?
Pharmaceutical companies conduct longitudinalstudies on human subjects that often span several months. It is unrealistic to expect patients to keep every scheduled visit over such a long period of time.Despite every effort, patient data are not collected for some time points. Eventually, these become missing values in a SAS data set later. For reporting purposes,the most recent previously available value is substituted for each missing visit. This is called the Last Observation Carried Forward (LOCF).LOCF doesn’t mean last SAS dataset observation carried forward. It means last non-missing value carried forward. It is the values of individual measures that are the “observations” in this case. And if you have multiple variables containing these values then they will be carried forward independently.
48) ETL process:
Extract, transform and Load:
The 1st part of an ETL process is to extract the data from the source systems. Most data warehousing projects consolidate data from different source systems.
Each separate system may also use a different data organization / format. Common data source formats are relational databases and flat files, but may include non-relational database structures such as IMS or other data structures such as VSAM or ISAM.
Extraction converts the data into a format for transformation processing.An intrinsic part of the extraction is the parsing of extracted data, resulting in a check if the data meets an expected pattern
Transform:The transform stage applies a series of rules or functions to the extracted data from the source to derive the data to be loaded to the end target. Some data sources will require very little or even no manipulation of data. In other cases, one or more of the following transformations types to meet the business and technical needs of the end target may be required:·
Selecting only certain columns to load (or selecting null columns not to load) · Translating coded values (e.g., if the source system stores 1 for male and 2 for female, but the warehouse stores M for male and F for female), this is called automated data cleansing; no manual cleansing occurs during ETL · Encoding free-form values (e.g., mapping “Male” to “1” and “Mr” to M) ·
Joining together data from multiple sources (e.g., lookup, merge, etc.) · Generating surrogate key values · Transposing or pivoting (turning multiple columns into multiple rows or vice versa) · Splitting a column into multiple columns (e.g., putting a comma-separated list specified as a string in one column as individual values in different columns) ·
Applying any form of simple or complex data validation; if failed, a full, partial or no rejection of the data, and thus no, partial or all the data is handed over to the next step, depending on the rule design and exception handling. Most of the above transformations itself might result in an exception, e.g. when a code-translation parses an unknown code in the extracted data.Load:The load phase loads the data into the end target, usually being the data warehouse (DW).
Depending on the requirements of the organization, this process ranges widely. Some data warehouses might weekly overwrite existing information with cumulative, updated data, while other DW (or even other parts of the same DW) might add new data in a historized form, e.g. hourly. The timing and scope to replace or append are strategic design choices dependent on the time available and the business needs. More complex systems can maintain a history and audit trail of all changes to the data loaded in the DW.
As the load phase interacts with a database, the constraints defined in the database schema as well as in triggers activated upon data load apply (e.g. uniqueness, referential integrity, mandatory fields), which also contribute to the overall data quality performance of the ETL process.